CJC-1295 with DAC: Mechanism of Action

Introduction

CJC-1295 with DAC is a synthetic peptide compound classified as a GHRH analog that interacts with the growth hormone-releasing hormone receptor (GHRH-R) on anterior pituitary somatotrophs. Its reported mechanism of action encompasses two distinct but interrelated components: the pharmacological action at the GHRH receptor and the albumin-conjugation chemistry of the Drug Affinity Complex (DAC) that governs its pharmacokinetics. This article reviews the published molecular pharmacology of CJC-1295 with DAC as reported in peer-reviewed literature.

Receptor Target and Pathway

The primary molecular target of CJC-1295 with DAC is the GHRH receptor (GHRH-R), a class B1 secretin-family G protein-coupled receptor (GPCR) predominantly expressed on somatotroph cells of the anterior pituitary gland. Frohman and Kineman (2025) reviewed GHRH-R structure and signaling, characterizing it as a receptor with seven transmembrane helices and a large N-terminal extracellular domain that engages the N-terminal alpha-helical region of GHRH peptides [1]. The receptor is coupled primarily to the stimulatory Gs alpha subunit.

Upon ligand binding, GHRH-R undergoes conformational change that activates adenylyl cyclase via Gs-alpha, catalyzing the conversion of ATP to cyclic adenosine monophosphate (cAMP). This second-messenger signal activates protein kinase A (PKA), which in turn phosphorylates the transcription factor CREB (cAMP response element-binding protein) and triggers voltage-gated calcium channel opening in the somatotroph plasma membrane. Calcium influx drives exocytosis of GH from secretory granules, while CREB-mediated transcription sustains GH gene expression over longer time scales [1].

CJC-1295 with DAC acts as an agonist at GHRH-R through the same receptor pathway as native GHRH, with reported superior stability against the proteolytic inactivation that limits native peptide action. The GHRH receptor pathway is distinct from the ghrelin receptor (GHS-R1a) pathway engaged by peptides such as ipamorelin, which stimulate GH secretion through a separate molecular mechanism.

The DAC Conjugation Chemistry

The DAC modification is the structural feature that sets CJC-1295 with DAC apart from other GHRH analogs at the molecular level. Bhatt and colleagues (2005) characterized the conjugation chemistry in detail: an N-epsilon-3-maleimidopropionamide group is appended via a lysine residue at the C-terminus of the tetra-substituted GHRH(1-29) peptide [2]. This maleimide group undergoes a highly selective Michael addition reaction with free thiol groups — specifically the Cys34 residue of human serum albumin (HSA) — forming a stable covalent thioether bond.

The authors reported that this albumin conjugation resulted in markedly enhanced in vitro stability against DPP-4 degradation for the conjugated species relative to unconjugated hGRF(1-29) [2]. The albumin-conjugated form retained biological activity: all three maleimido-derivatized conjugates tested activated the GRF receptor on anterior pituitary cells in rat models, with CJC-1295 yielding a 4-fold increase in GH area under the curve compared with hGRF(1-29) [2].

The selectivity of the maleimide reaction for Cys34 on albumin is a key mechanistic feature. HSA possesses a single free cysteine at position 34 that is accessible in the native protein structure, making it the dominant conjugation site for thiol-reactive maleimide compounds in plasma. This selectivity underpins the predictable pharmacokinetic extension that the DAC platform was designed to deliver.

Reported Downstream Effects in Human Studies

The most clinically translatable mechanistic data were reported by Teichman and colleagues (2006) in healthy adult volunteers [3]. The study observed that CJC-1295 produced sustained, pulsatile GH secretion measurable for six days or longer following a single administration, with concurrent elevations in plasma insulin-like growth factor 1 (IGF-1) lasting nine to eleven days [3]. Findings from this research model do not establish safety or efficacy in humans. SpartaLabs makes no claims about the use of this compound.

A subsequent investigation by Ionescu and Frohman (2006) examined the GH secretory pattern during CJC-1295 exposure in more detail [4]. The authors reported that pulsatile GH secretion was maintained during sustained CJC-1295 stimulation rather than being replaced by tonic, non-pulsatile GH release. The observed pattern included increases in GH pulse amplitude and trough concentrations while preserving the episodic secretory character — a contrast to the pattern associated with exogenous GH administration, which suppresses endogenous pituitary secretion [4].

Sackmann-Sala and colleagues (2009) applied serum proteomics to characterize downstream molecular changes in healthy adult men one week after CJC-1295 administration [5]. Using two-dimensional gel electrophoresis and mass spectrometry, the investigators identified several proteins whose circulating concentrations were altered and reported a linear relationship between IGF-1 levels and one identified protein cluster. The authors proposed that the identified proteins could serve as potential biomarkers of GH and IGF-1 biological activity [5].

Areas of Ongoing Investigation

Several aspects of CJC-1295 with DAC's molecular pharmacology remain active areas of investigation in the published literature.

The precise structural determinants of CJC-1295's GHRH-R agonism at atomic resolution have not yet been characterized by crystallography or cryo-electron microscopy, a frontier that continues to advance for class B GPCR ligands broadly. Defining these interactions would further illuminate the contributions of each amino acid substitution in the tetra-substituted scaffold to receptor binding affinity and selectivity.

The neuroendocrine mechanisms underlying pulsatile GH secretion under sustained GHRH-R agonism — observed by Ionescu and Frohman and likely involving somatostatin counter-regulation — represent an open and scientifically interesting question for somatotroph biology [4]. The pharmacokinetics of the albumin conjugate across varied populations (altered albumin levels, renal or hepatic variation) offer another frontier for future characterization. The published research underlying these mechanistic observations is further reviewed in the CJC-1295 with DAC published research article, and CJC-1295 with DAC is available from SpartaLabs with batch-level analytical documentation.

References

1. Frohman LA, Kineman RD. Growth hormone-releasing hormone receptor (GHRH-R) and its signaling. Rev Endocr Metab Disord. 2025. PMC: PMC12137518.

2. Bhatt DL, Bhatt S, Gagnon C, Castaigne JP, Frohman LA. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(9):3810-3818. PMID: 15817669. DOI: 10.1210/en.2004-1611.

3. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683. DOI: 10.1210/jc.2005-1536.

4. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 16968793. DOI: 10.1210/jc.2006-1702.

5. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. PMID: 19386527. PMC: PMC2787983. DOI: 10.1016/j.ghir.2009.03.001.